Valeant Completes Amendment to Credit Facility
Date: 02/13/12
Cahill represented the arrangers and administrative agent in connection with a $600,000,000 Tranche B Term Loan Facility for Valeant Pharmaceuticals International, Inc. The loan will be added to the existing $2.5 billion credit facility comprised of a $1,225,000,000 Term A loan, a $275,000,000 revolving credit facility, a $500,000,000 delayed draw term loan and a $500,000,000 Incremental Term Loan Facility. Proceeds will be used to refinance existing indebtedness, finance acquisitions, and for general corporate purposes.